Gollob Jared, Chief Medical Officer at Kymera Therapeutics (KYMR), has demonstrated a pronounced selling bias in recent insider transactions, with no recorded purchases since at least October 2025. Over 25 reported trades, his total sell activity amounts to $9.13 million, dwarfing his $349,440 in buys. The bulk of his disposals occurred in concentrated clusters, most notably on December 8, 2025, when he sold $4.35 million worth of KYMR shares across six transactions, including a single $1.62 million sale. This was followed by another significant divestment on March 4, 2026, totaling $417,521 in four sales. Earlier, on October 15, 2025, he offloaded $3.66 million in KYMR stock through four sales, with the largest being $1.77 million.
The transactions suggest a consistent unwinding of positions, with no offsetting buys in the observed period. While two March 2026 filings show $0 value transactions (coded "A" for award grants), the overall pattern leans heavily toward liquidation. Smaller sales, such as $186,840 on October 13, 2025, and $273,276 on March 2, 2026, further reinforce this trend. The absence of purchases during this timeframe—particularly given Jared’s executive role—may signal portfolio rebalancing or personal liquidity needs, though the filings provide no explicit rationale. KYMR remains the sole equity in his reported trading activity.
AI-assisted summary